About Orthocell
Orthocell is a company based in Perth (Australia) founded in 2006 by Paul Anderson.. Orthocell offers products and services including Striate+™, Remplir™, OrthoACI™, and Tendon. Orthocell operates in a competitive market with competitors including Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others.
- Headquarter Perth, Australia
- Founders Paul Anderson
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orthocell Limited
-
Annual Revenue
$4.93 M (USD)42.05as on Jun 30, 2025
-
Net Profit
$-5.6 M (USD)-19.3as on Jun 30, 2025
-
EBITDA
$-8.41 M (USD)-15.37as on Jun 30, 2025
-
Latest Funding Round
$11.16 M (USD), Post-IPO
Oct 30, 2024
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Orthocell
Orthocell is a publicly listed company on the ASX with ticker symbol OCC in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Orthocell
Orthocell offers a comprehensive portfolio of products and services, including Striate+™, Remplir™, OrthoACI™, and Tendon. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Regenerative membrane for dental repair and tissue healing.
Device for nerve regeneration and injury support.
Therapy for cartilage regeneration in joint injuries.
Product for tendon healing and mobility restoration.
Unlock access to complete
Unlock access to complete
Funding Insights of Orthocell
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $11.2M
-
First Round
First Round
(30 Oct 2024)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Post-IPO - Orthocell | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Orthocell
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Orthocell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orthocell Comparisons
Competitors of Orthocell
Orthocell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for bone regeneration are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for muscle, bone, and joint diseases are developed.
|
|
| domain | founded_year | HQ Location |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Stem cell-based regenerative medicines are developed and marketed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orthocell
Frequently Asked Questions about Orthocell
When was Orthocell founded?
Orthocell was founded in 2006 and raised its 1st funding round 18 years after it was founded.
Where is Orthocell located?
Orthocell is headquartered in Perth, Australia. It is registered at Perth, Western Australia, Australia.
Who is the current CEO of Orthocell?
Paul Anderson is the current CEO of Orthocell. They have also founded this company.
What is the annual revenue of Orthocell?
Annual revenue of Orthocell is $4.93M as on Jun 30, 2025.
What does Orthocell do?
Orthocell was founded in 2006 in Perth, Australia, and focuses on regenerative medicine within the orthopedic sector. Collagen-based products are developed for tissue repair applications. Striate serves as a resorbable membrane for dental procedures, while Remplir functions as a scaffold for peripheral nerve regeneration. OrthoACI is utilized for autologous chondrocyte implantation to address cartilage defects in the knee and ankle. Operations center on advancing these therapies for clinical use.
Who are the top competitors of Orthocell?
Orthocell's top competitors include Horizon Therapeutics, ZetaGen and Angitia.
What products or services does Orthocell offer?
Orthocell offers Striate+™, Remplir™, OrthoACI™, and Tendon.
Is Orthocell publicly traded?
Yes, Orthocell is publicly traded on ASX under the ticker symbol OCC.
What is Orthocell's ticker symbol?
The ticker symbol of Orthocell is OCC on ASX.